Autonomix Medical Reports $3.3 Million Net Loss and Increased Operating Expenses for Q2 2025

Autonomix Medical, Inc. reported a net loss of $3.3 million for the three months ended June 30, 2025, compared to a loss of $2.7 million during the same period in 2024. The company's total operating expenses increased by 24% to $3.4 million, driven primarily by a 67% rise in research and development costs, which reached $1.6 million, reflecting ongoing clinical trial and product development efforts. General and administrative expenses remained relatively stable at $1.8 million, showing only a slight increase from the previous year.

The company’s financial position as of June 30, 2025, showed total assets of $9.0 million, a decrease from $9.8 million at the end of the previous fiscal quarter. Current liabilities rose to $2.0 million, up from $1.7 million, primarily due to increases in accounts payable and accrued expenses. Autonomix's cash and cash equivalents stood at $8.6 million, which the company estimates will fund operations into the second quarter of 2026. The accumulated deficit increased to $53.7 million, reflecting the ongoing losses since inception.

In terms of strategic developments, Autonomix has made significant progress in its clinical trials. The company completed its initial first-in-human proof-of-concept study for its Elpis System, which targets pain associated with pancreatic cancer. Following positive results, Autonomix has expanded its clinical focus to include patients with other visceral cancers. The company also received FDA guidance on its regulatory pathway, aiming for potential De Novo approval by 2028.

Operationally, Autonomix has been active in enhancing its product offerings and intellectual property. The company issued two new U.S. patents related to its technology for neuromodulation, which supports its long-term strategy to protect innovations and expand into adjacent medical indications. Additionally, Autonomix entered into a warrant exercise inducement agreement, which resulted in gross proceeds of approximately $2.6 million, further bolstering its financial resources.

Looking ahead, Autonomix acknowledges the need for additional capital, estimating a requirement of $32 to $40 million to support its operations through to commercialization. The company recognizes that its ability to raise sufficient funds will be critical to executing its business plan, including obtaining regulatory clearance for its products and generating revenue. The management has indicated that failure to secure additional financing could necessitate scaling back operations, raising concerns about the company's ability to continue as a going concern.